Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines

Gandhi, Ajeet Kumar; Naziruddin, S.; Verhelle, Dominique; Brady, H.; Schafer, PH; Stirling, David

doi:10.1200/jco.2004.22.90140.6618

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 In this study, 64% of 148 RBC transfusion-dependent patients with del(5q31) MDS achieved transfusion independence, and the rate of transfusion independence was higher in patients with an isolated del(5q) than in del(5q) patients with additional chromosomal abnormalities (69% [n ϭ 111] v 49% [n ϭ 37]; P ϭ .003). 70,71 Lenalidomide may also decrease erythropoietin signaling in del(5q) cells, triggering their apoptosis. Neutropenia and thrombocytopenia were the most common adverse events in this study, necessitating treatment interruption or dose reduction.…”

Section: Lenalidomidementioning

confidence: 99%

Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q

Nimer

2006

JCO

View full text Add to dashboard Cite

Deletions of the long (q) arm of chromosome 5 [del(5q)]occur in patients with myelodysplastic syndromes (MDS) including, but not limited to, those who meet the WHO definition of the 5q- syndrome. Del(5q) MDS patients frequently have symptomatic anemia, and its treatment has traditionally consisted of RBC transfusions and, for some, iron chelation therapy. Erythropoietin, darbepoetin, hypomethylating agents, and lenalidomide can enhance erythropoiesis in MDS patients with anemia, increasing hemoglobin levels and abrogating RBC transfusion requirements. Lenalidomide is particularly active in treating the anemia of del(5q) MDS, which is especially relevant given the low response rate to erythropoietin in this group of patients. In a recent study of 43 MDS patients, 10 of 12 patients (83%) with del(5q) MDS achieved sustained RBC transfusion independence (or a > 2 g/dL increase in hemoglobin), compared with 57% of those with a normal karyotype and 12% of those with other karyotypic abnormalities. Complete cytogenetic remissions were achieved in 75% (nine of 12) of the del(5q) MDS patients, suggesting that lenalidomide targets a fundamental pathogenetic feature of MDS that is more pronounced in the presence of chromosomal 5q deletions. This review highlights some issues about the classification and treatment of del(5q) MDS.

show abstract

Section: Lenalidomidementioning

confidence: 99%